Please enable JavaScript.
Coggle requires JavaScript to display documents.
NLR and Cancer (Lymphocyte Count (Prostate Cancer (The relationship…
NLR and Cancer
Lymphocyte Count
Lung Cancer
Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer 2013
the prognostic value of cancer-related inflammatory response has been revealed. Previous studies showed that peripheral neutrophils and lymphocytes had significant impact on the prognosis of advanced and early-node-negative non-small-cell
Breast Cancer
Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer 2012
Change in total lymphocyte count as function of initial value … About half of all patients not radiated have lymphocyte counts nearly double their preoperative levels two years later.
Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer 1989
Patients with lymphocyte counts less than or equal to 1500/mm3 and/or eosinophil counts of less than 55/mm3 had significantly higher risk of recurrent disease than those patients who had normal or high levels of eosinophils and/or lymphocytes.
Head and Neck Cancer
Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer 1976
The present data suggest DNCB reactivity is helpful in predicting outcome after surgery, or combined radiation and surgery, for mucosal squamous carcinoma of the head and neck.
Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy 1976
Patients with advanced lesions usually received radiation to larger areas than patients with localized lesions; therefore, the extent of decline in laboratory values was most likely dependent on volume of tissue treated.
Stomach Cancer
Absolute granulocyte, lymphocyte, and monocyte counts: useful determinants of prognosis for patients with metastatic cancer of the stomach 1982
Pretreatment absolute granulocyte (<6,000/cu mm), lymphocyte (>1,500/cu mm), and monocyte (300 to 900/cu mm) counts are three independent indicators of good prognosis for patients with metastatic gastric cancer.
Ovarian Cancer
Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes 2012
Patients with high intrinsic ALC values show no clinical or survival advantage upon subsequent development of HGSC. ALC values at diagnosis are prognostic due to an association with disease burden rather than TIL. Therapeutic enhancement of ALC may be necessary but not sufficient to improve survival in HGSC.
Prostate Cancer
The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer 2004
Increased CD4+ T-lymphocyte infiltration within the tumour was stage independent and associated with poor outcome in patients with prostate cancer.
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers 2005
Immunotherapy may provide valid alternative therapy for patients with hormone-refractory metastatic prostate cancer. However, if the tumor environment exerts a suppressive action on antigen-specific tumor-infiltrating lymphocytes (TIL), immunotherapy will achieve little, if any, success.
Targeted elimination of prostate cancer by genetically directed human T lymphocytes 2005
These results thus provide a strong rationale for undertaking phase I clinical studies to assess PSMA-targeted T cells in patients with metastatic prostate cancer.
-
-
Neutrophil Count
Colerectal Cancer
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer 2011
These results have highlighted NLR as a potentially useful clinical biomarker of systemic inflammatory response in predicting clinically meaningful outcomes in two independent cohorts.
Breast Cancer
Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer 2000
These data demonstrate that PBPCs expanded under the conditions defined can shorten the time to engraftment of neutrophils compared with historical controls and that the rate of engraftment is related to the dose of expanded cells transplanted.
Prostate Cancer
Neutrophil count is associated with survival in localized prostate cancer 2015Neutrophil count, as a possible marker of systemic inflammation, appear to be an independent prognostic factor for overall mortality in localized prostate cancer. A validation cohort is needed to corroborate these results
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review 2016
Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer
Neutrophils, a candidate biomarker and target for radiation therapy? 2017
Neutrophils are the most abundant blood-circulating white blood cells, continuously generated in the bone marrow. Growing evidence suggests they regulate the innate and adaptive immune system during tumor evolution.
A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer 2017
It has been shown that neutrophil count or an elevated neutrophil-to-lymphocyte ratio (NLR) as well as testosterone levels are separately associated with increased mortality in patients with localized prostate cancer.
-
Lung Cancer
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer 200900048-3/abstract)
Neutrophil count is easily measured at low cost, and it may be a useful indicator of patient prognosis.
Gastric Cancer
Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy 2014
To explore the value of systemic inflammatory markers as independent prognostic factors and the extent these markers improve prognostic classification for patients with inoperable advanced or metastatic gastric cancer
-